Best Non-Hodgkin's lymphoma hematologist-oncologists: TOP 77 doctors

Dr. Toluy Özgümüş has graduated from Istanbul University, Cerrahpaşa Faculty of Medicine in 2008 and completed his internal medicine specialty training at Haydarpaşa Numune Training and Research Hospital between 2009 and 2013. He received his Hematology subspecialty training at Marmara University Hematology Department between 2014-2017; He performed his compulsory service at Kars Harakani State Hospital between 2017-2019. He worked at Sancaktepe Şehit Prof. Dr. Ilhan Varak Training and Research Hospital between 2019-2023.

He is experienced in the field of bleeding and coagulation disorders, especially coagulation disorders (thrombophilia), and has dealt with the diagnosis and treatment of more than 1000 patients. Since he worked in the pandemic hospital of the Anatolian side of Istanbul during the pandemic period, he has extensive experience in the hematological findings of Covid-19 infection and the management of Covid-19 infection in hematological diseases. Hundreds of patient experiences are available in the diagnosis of myeloproliferative diseases such as Polycythemia Vera and Essential Thrombocytosis, in their differentiation from blood cell elevations due to other frequently confused causes, and in their treatment. He has experience in the diagnosis and all treatment processes of rare hematological cancers such as multiple myeloma, acute and chronic leukemias, lymphomas and histiocytosis, as well as .

MEDICAL INTERESTS 

Clotting Disorders (Thrombophilia)

Bleeding Disorders

Myeloproliferative Diseases

Anemias (Anemia)

Acute and Chronic Leukemias

lymphomas

Assoc. Prof. Dr. Oğuzhan BABACAN completed his undergraduate, specialty and sub-specialty education at GATA Military Medical Faculty/Ankara. After becoming a specialist in Pediatrics, he worked in the field of Social Pediatrics for two years, where Healthy Baby Monitoring and vaccine follow-up were carried out. Then, she completed her subspecialty training in Pediatric Hematology and Oncology and continued her studies in the field of pediatric blood and cancer diseases. In addition to the treatment of children suffering from leukemia, lymphoma, solid tumors and other blood diseases, she has been working in the (Transplant) Unit for 13 years in (unrelated and intrafamilial), (from the patient himself) and Haploidentical (partially HLA compatible) hematopoietic transplantation. In 2018, he received the title of Associate Professor in the field of Pediatric Hematology and Oncology Science/Art.

MEDICAL AREAS OF INTEREST

Healthy baby follow-up and vaccinations

Lymph node enlargement

Pediatric patients with anemia (anemia)

Leukemia

Lymphoma

Transplant

ITP

Thalassemias

Hemophiliacs

Solid tumors

Hemangioma

Childhood blood disorders

Children with frequent infections

Fever of unknown origin

Malnutrition in children

Prof. Dr. Şebnem İzmir Güner was born in 1970 in Istanbul and took her first steps in her medical career at Istanbul University Faculty of Medicine. Successfully completing her undergraduate and medical education here between 1987-1993, Güner received her internal medicine specialty training at Istanbul University Cerrahpaşa Faculty of Medicine from 1995 to 2000. Deepening her interest in hematology, Prof. Dr. Güner completed her hematology subspecialty training at Cerrahpaşa Faculty of Medicine again between 2003-2006, solidifying her expertise in this field.
Prof. Dr. Güner’s professional journey began as an internal medicine specialist at Istanbul Education and Research Hospital from 2000 to 2003. She established the Hematology Clinic at the same hospital from 2006 to 2010 and served as the responsible physician. Here, she developed innovative approaches in the treatment of patients and made significant contributions to the field of hematology. From 2010 to 2016, she established the Hematology Clinic, Therapeutic Apheresis, and Adult Center at Medicalpark Bahçelievler Hospital and served as the responsible physician. During this period, she conducted studies that set national and international standards in the field of hematology.
Between 2016-2018, Prof. Dr. Güner took on similar roles at Şişli Kolon International Hospital, where she was also the founder and responsible physician of the Hematology Clinic, Therapeutic Apheresis, and Adult Center. Güner, who became an associate professor in 2017, obtained her professorship title in 2023. Between 2019-2024, she worked at Memorial Şişli Hospital in the Hematology Clinic, Therapeutic Apheresis, and Adult Center.
Prof. Dr. Şebnem İzmir Güner is recognized for her scientific contributions, with over 19 articles published in international peer-reviewed journals. Additionally, she has over 18 articles published in national peer-reviewed journals and 51 presentations at national scientific meetings that have been published in proceedings books. She has also made a name for herself in the academic world with over 18 presentations at meetings and published in proceedings books. Güner, who has held positions on the boards of domestic hematology associations and has active memberships, has crowned her success with more than three awards given at universities and conferences.
Prof. Dr. Şebnem İzmir Güner, who speaks English and German, is also recognized as an educator. In this capacity, she has contributed to the training of young doctors in the field of hematology, providing education to research assistant doctors and students.
Prof. Dr. Şebnem İzmir Güner has established a respected place in the field of hematology with her achievements and scientific contributions throughout her professional life, continuing her career as a physician who inspires her patients and colleagues.

MEDICAL INTERESTS

• Leukemia
• Lymphoma
• Multiple myeloma
• Anemia
• Bleeding and coagulation disorders
• Hemophilia

Dr. Francesc Cobo Valien graduated from the Faculty of Medicine of the University of Barcelona in 1990.

He received his specialization in oncohematology at the Hospital Clínic de Barcelona in 1995. He combined medical practice and research activities in the period 1996-2002.

He received his Doctor of Medicine degree from the University of Barcelona in 2002.

Dr. Kobo continues his research and has been awarded grants:

•Interdepartmental Commission for Innovation of the Generalitat de Catalunya

•Scholarship Fund Universitaria Agustí Pedro i Pons

•Farreras Valentí & Schering Plough School of Hematology Scholarship

•Award for the best report at the Council of the Spanish Hematology Association

•Grant from the Catalan Society of Hematology

Specialization:

•Lymphoma

•Acute leukemia

•Chronic leukemia

•Autoimmune pancytopenia

Education:

2015

Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology 

2010

Dokuz Eylül University, Medical Faculty, Internal Medicine 

2005

Hacettepe University, Medical Faculty,

Experience:

2024 – 

Istanbul Florence Nightingale Hospital

2017 – 2024

Bağcılar Medipol University Hospital

2017 – 2017

Fırat University

2015 - 2017

Fırat University

2014 - 2015

Mayo Clinic

Publications:

18 Articles Published in International Peer-Reviewed Journals

26 Abstracts and Books Presented at International Scientific Conferences

7 Articles Published in National Peer-Reviewed Journals

51 Abstracts Presented at National Scientific Conferences

Dr. Andrés J.M. Ferreri is a medical oncologist with over 300 scientific papers published related to lymphoma treatment. He is a Deputy Director at the Hematology Oncology Department and Director of the Lymphoma Unit at the San Raffaele Scientific Institute, as well as Founder of the Italian Lymphoma Foundation. He is a member of various prestigious medical organizations and a Contract Professor of Oncology at the Università Vita-Salute San Raffaele.

Dr. Dror Levin is a senior pediatrician and director of the blood disorder and bone cancer (sarcoma) treatment departments at Children's Hospital "Dana" and Medical Center "Sourasky" respectively. He is a specialist in pediatric medicine, hematology, and oncology, with additional experience studying abroad at the Rizzoli Orthopaedic Institute in Italy.

Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

Education and Expertise

Ankara University Faculty of Medicine - Medical Education

Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization

Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty

Duke University Center - Cell Transplantation Training

Fred Hutchinson Cancer Research Center Seattle - Cell Transplant Training

Experience

Duke University-Durham North Carolina program 2001, cord blood transplant

Fred Hutchinson Cancer Research Center program Seattle 2002, unrelated transplant

Founder and manager of Gazi University Faculty of Medicine Adult Cell Transplant Unit 2003-2014

Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014

Gazi University Faculty of Health Sciences Dean (founder) 2008-2012

Professional Memberships

Turkish Hematology Association





Bilimsel Yayınları

1.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. haematopoietic transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the E.
     Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
2.    Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Hematopoietic Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
3.    Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
4.    Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201. 
5.    Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
6.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. haematopoietic transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the E. Transplant. 2017 Feb;52(2):209-215. Erratum in: Transplant. 2017 Jul;52(7):1081.
7.    Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80. 
8.    van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
9.    Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Transplant. 2016 Mar;51(3):384-90. 
10.    Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of E. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative transplantation: a report from the acute leukemia working party of E. Transplant. 2016 Mar;51(3):351-7. 
11.    Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
12.    Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40. 
13.    Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in hematopoietic transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
14.    Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015  Apr 28.
15.     Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20. 
16.    Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
17.    Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
18.    Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
19.    Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
20.    Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. and Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the E Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
21.    Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
22.    Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
23.    Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62. 
24.    Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Hematopoietic Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
25.    Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Syic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318   Pages 323 – 324
26.    Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
27.    Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
28.    Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
29.    Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
30.    Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
31.    Keser I, Suyani E, Aki SZ,  Sucak AG. The positive impact of regular exercise program on mobilization prior to autologous transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
32.    Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.  Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
33.    Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
34.    Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
35.    Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
36.    Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous -cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
37.    Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
38.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after hematopoietic SCT. A study of the late effects working party of the E. Transplant. 2013 Jun;48(6):878-9.
39.    Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after hematopoetic transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
40.    Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
41.    Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
42.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the E. Ongoing graft-versus-host disease is a risk factor for azoospermia after hematopoietic transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
43.    Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
44.    Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of hematopoetic transplantation? Minerva Med. 2012 Jun;103(3):189-98.
45.    Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
46.    Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in hematopoietic transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
47.    Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
48.    Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
49.    Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human -derived mesenchymal .J Endocrinol. 2012 Feb;212(2):169-78.
50.    Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
51.    Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
52.    Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
53.    Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
54.    Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
55.    Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
56.    Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
57.    Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
58.    Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
59.    Ljungman P,  de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic -cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
60.    Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
61.    Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
62.    Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
63.    Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
64.    Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
65.    Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
66.    Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
67.    Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
68.    Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic transplantation recipients: the role of iron overload. Transplant. 2010 Oct;45(10):1528-33.
69.    Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.

Professor Drach is a specialist in oncology with a PhD from the Medical University of Vienna. He has experience in research, internal medicine, hematologic oncology, nutrition, and lifestyle in cancer. He is the Director of the Josefstadt Private Clinic in Vienna and a member of the Board of Directors of the Austrian Society of Hematology and Oncology. He has published more than 120 scientific papers and given more than 200 lectures/presentations.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Medical Fields of Interest: 

Chronic Leukemia (Chronic Lymphocytes Leukemia/ Chronic Myeloid Leukemia) 

Chronic Myeloproliferative Diseases (Poliia Vera, Essential Thrombocytosis, Myelofibrosis etc.) 

Lymphoma (Hodgkin’s and Non-Hodgkin’s) 

Multiple Myeloma 

Education: 

Ege University Faculty of Medicine Medical Doctor 1999 - 2005 

Pamukkale University Specialist in Internal Medicine 2006 - 2011 

Pamukkale University Hematologist 2011 - 2014 

ESCCA Summer School On Cytometry/PRAGUE (May 2014) 

Istanbul Training and Research Hospital Hematology Clinic Associate Professor 2018 

Experience: 

Selçuk University Faculty of Medicine Hospital 2015 

Pamukkale University Internal Medicine Residency Training 2016 - 2011 

Denizli Sarayköy State Hospital 2011 - 2011 

Pamukkale University Hematology Minor Residency Training 2011 - 2014 

Istanbul Training and Research Hospital Hematology Clinic Specialist Doctor 2015 - 2020 

Istanbul Training and Research Hospital Hematology Clinic Responsible Authority 2015 - 2020 

Istanbul Training and Research Hospital Hematology Clinic Responsible Authority/ Lecturer 2019 - 2020 

Istanbul Başakşehir Çam and Şakura City Hospital Hematology Clinic Lecturer 2020 - 2020

Liv Hospital Ulus 2020-

Memberships: 

Turkish Society of Hematology 

The Society of Hematological Education and Research (Member of The Board of Directors

Publications:

32 articles published in international peer-reviewed journals 

12 cases published in international peer-reviewed journals 

11 articles published in national peer-reviewed journals 

5 cases published in national peer-reviewed journals

Education

• Undergraduate: Istanbul Faculty of Medicine, Istanbul University, 2007
• MSc (Internal Medicine Department): Marmara University Faculty of Medicine, 2012
• PhD (Hematology Clinic): Istanbul Training and Research Hospital, 2018
• Associate Professor (Hematology Clinic): Prof.Dr.Cemil Tascioglu Training and Research Hospital, 2019

Prof. Dr. Rafet Eren graduated from Istanbul Faculty of Medicine in 2007. He completed his Internal Medicine specialty training at Marmara University Faculty of Medicine in 2012. In 2018, he became a Hematology subspecialist at Istanbul Training and Research Hospital. In 2019, he was awarded the title of Associate Professor in the field of Hematology. Afterwards, he worked as a faculty member at Başakşehir Çam and Sakura City Hospital, Bozyaka Training and Research Hospital and Istinye University (Istinye University Bahçeşehir and Liv Hospital Vadistanbul) and is currently working at Biruni University Hospital. Dr. Rafet Eren is a member of Turkish Society of Hematology, Hematology Specialty Society and European Society of Hematology and speaks English fluently. He has around 50 publications in national and international refereed journals.

Scientific Memberships

• Turkish Hematology Association
• Hematology Specialty Society
• Turkish Internal Medicine Specialty Society
• European Society of Hematology
•  

Awards 

• Young Researcher Award (42nd National Hematology Congress), 2016
• Special Jury Paper Award (3rd Hematologic Oncology Congress), 2015
• Paper 3rd Prize (2nd Hematologic Oncology and Symposium), 2016

Education

• Faculty of Medicine - Cerrahpaşa Faculty of Medicine 1999-2005
• Internal Medicine Residency - Istanbul Haseki Training and Research Hospital 2006-2010
• Hematology Subspecialist Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital - Hematology and Cell Transplant Clinic 2013-2017
• Associate ProfessorIstanbul Ümraniye Training and Research Hospital 2019
•  

Experience

• Assistant Doctor Istanbul Haseki Training and Research Hospital - Internal Medicine Clinic 2006-2010
• Internal Medicine Specialist Istanbul Esenyurt State Hospital 2010-2012
• Internal Medicine Specialist-Military service Samsun Military Hospital 2012-2013
• Subspecialty Training Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital - Hematology and Cell Transplant Clinic 2013-2017
• Hematology Subspecialist Ankara Gülhane Training and Research Hospital, Hematology and Cell Transplant Clinic 2017-2018
• Hematology Subspecialist Istanbul Ümraniye Training and Research Hospital/Hematology 2018-2019
• Associate Professor Istanbul Ümraniye Training and Research Hospital/Hematology 2019-2021
• Associate Professor Maltepe University Faculty of Medicine / Hematology 2021-2024
• Associate Professor Istanbul VM Medical Park Pendik Hospital / Hematology and Cell Transplant Clinic 2022-2024
•  

Scientific Memberships

• Turkish Medical Association
• Turkish Apheresis Society
• Hematologic Oncology Society
• Blood and Transplant Association
• Hematologic Immunology Society
•  

Awards

•  
• Hematologic Oncology Society, 2015 - Second Prize for Paper
• Hematologic Oncology Society, 2016 - Second Prize for Paper
• Turkish Apheresis Association, 2016 - Paper Third Prize,
• Hematologic Immunology Association, 2016 - Second Prize for Paper
• Hematologic Oncology Society, 2016 - Second Prize for Paper
• Blood and Association, 2017 - First Prize for Paper